New vaccine to prevent herpes zoster
The ANMAT authorized this week the start of Phase II and III studies of the ARVAC Cecilia Grierson vaccine. They estimate that this year it could be approved for its application
Chickenpox and herpes zoster have the same origin: the varicella-zoster virus. In the first infection, this virus causes chickenpox by remaining latent in the sensory nerves, responsible for perceiving the temperature or the touch of objects. Our immune system keeps the virus under control, but sometimes it stops being able to control it and reactivates as herpes zoster.
Its expected that a new vaccine against herpes zoster is available in Argentina in March of this year. The precise date will depend on the process of the regulatory paperwork presented before the National Administration of Medicines, Food and Medical Technology (ANMAT).
With the intention that it be authorized during 2023, the Ministry of Health announced the start of the next stage of clinical trials.
The biotech giant GSK, in Wavre, produces a portfolio of more than 20 vaccines to protect people from the spread of infectious diseases throughout their lives. The experts from the biotechnological plant anticipated this medium, which was advancing at a steady pace in the production of the shingles vaccine for adults. GSK is working to make it available in Argentina in the first months of 2023.
The Centers for Disease Control and Prevention (CDC) recommends the vaccine shingrix from GSK for adults age 50 and over to prevent shingles and related complications, whether they have had the disease or not. It is also intended for people over 18 years of age with immunocompromised conditions. A person can receive the vaccine even if they have already had shingles.
The Shingrix vaccine has been approved by the Food and Drug Administration (FDA) and is more than 90% effective in preventing shingles and long-term neuropathic pain.